214 related articles for article (PubMed ID: 26763586)
1. Controlled multi-arm platform design using predictive probability.
Hobbs BP; Chen N; Lee JJ
Stat Methods Med Res; 2018 Jan; 27(1):65-78. PubMed ID: 26763586
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
4. A modest proposal for dropping poor arms in clinical trials.
Proschan MA; Dodd LE
Stat Med; 2014 Aug; 33(19):3241-52. PubMed ID: 24757049
[TBL] [Abstract][Full Text] [Related]
5. A predictive probability design for phase II cancer clinical trials.
Lee JJ; Liu DD
Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
7. Adding new experimental arms to randomised clinical trials: Impact on error rates.
Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
[TBL] [Abstract][Full Text] [Related]
8. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
Ryan EG; Lamb SE; Williamson E; Gates S
Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
[TBL] [Abstract][Full Text] [Related]
9. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents.
Yuan Y; Guo B; Munsell M; Lu K; Jazaeri A
Stat Med; 2016 Sep; 35(22):3892-906. PubMed ID: 27112322
[TBL] [Abstract][Full Text] [Related]
10. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
Bratton DJ; Phillips PP; Parmar MK
BMC Med Res Methodol; 2013 Nov; 13():139. PubMed ID: 24229079
[TBL] [Abstract][Full Text] [Related]
11. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
Wason JM; Trippa L
Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment ordering.
Serra A; Mozgunov P; Jaki T
Stat Med; 2023 Jul; 42(16):2841-2854. PubMed ID: 37158302
[TBL] [Abstract][Full Text] [Related]
13. Bayesian designs with frequentist and Bayesian error rate considerations.
Wang YG; Leung DH; Li M; Tan SB
Stat Methods Med Res; 2005 Oct; 14(5):445-56. PubMed ID: 16248347
[TBL] [Abstract][Full Text] [Related]
14. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
Lin J; Bunn V
Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
[TBL] [Abstract][Full Text] [Related]
15. New designs for the selection of treatments to be tested in randomized clinical trials.
Simon R; Thall PF; Ellenberg SS
Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
[TBL] [Abstract][Full Text] [Related]
16. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
Zhu H
J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
[TBL] [Abstract][Full Text] [Related]
17. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
Yu Z; Ramakrishnan V; Meinzer C
J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
[TBL] [Abstract][Full Text] [Related]
18. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
[TBL] [Abstract][Full Text] [Related]
19. Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials.
Bassi A; Berkhof J; de Jong D; van de Ven PM
Stat Methods Med Res; 2021 Mar; 30(3):717-730. PubMed ID: 33243087
[TBL] [Abstract][Full Text] [Related]
20. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
Colditz GA
Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
